Abstract
Dopamine agonists have been usually used as adjunctive therapy for the cure of Parkinsons disease. It is generally believed that treatment with these drugs is symptomatic rather than curative and it does not stop or delay the progression of neuronal degeneration. However, several dopamine agonists of the D2-receptor family have recently been shown to possess neuroprotective properties in different in vitro and in vivo experimental Parkinsons disease models. Here we summarize some recent molecular evidences underlining the wide pharmacological spectrum of dopamine agonists currently used for treating Parkinsons disease patients. In particular, the mechanism of action of different dopamine agonists does not always appear to be restricted to the stimulation of selective dopamine receptor subtypes since at least some of these drugs are endowed with antioxidant, antiapoptotic or neurotrophic properties. These neuroprotective activities are molecule-specific and may contribute to the clinical efficacy of these drugs for the treatment of chronic and progressive neurodegenerative diseases in which oxidative injury and/or protein misfolding and aggregation exert a primary role.
Keywords: Free radicals, oxidative stress, Parkinson's disease, Alzheimer's disease, beta amyloid, neurodegeneration, fibrils, neurotrophic factors, neurogenesis
Current Topics in Medicinal Chemistry
Title: Dopamine Receptor Agonists for Protection and Repair in Parkinsons Disease
Volume: 8 Issue: 12
Author(s): Giulia Ferrari-Toninelli, Sara A. Bonini, Giovanna Cenini, Giuseppina Maccarinelli, Mariagrazia Grilli, Daniela Uberti and Maurizio Memo
Affiliation:
Keywords: Free radicals, oxidative stress, Parkinson's disease, Alzheimer's disease, beta amyloid, neurodegeneration, fibrils, neurotrophic factors, neurogenesis
Abstract: Dopamine agonists have been usually used as adjunctive therapy for the cure of Parkinsons disease. It is generally believed that treatment with these drugs is symptomatic rather than curative and it does not stop or delay the progression of neuronal degeneration. However, several dopamine agonists of the D2-receptor family have recently been shown to possess neuroprotective properties in different in vitro and in vivo experimental Parkinsons disease models. Here we summarize some recent molecular evidences underlining the wide pharmacological spectrum of dopamine agonists currently used for treating Parkinsons disease patients. In particular, the mechanism of action of different dopamine agonists does not always appear to be restricted to the stimulation of selective dopamine receptor subtypes since at least some of these drugs are endowed with antioxidant, antiapoptotic or neurotrophic properties. These neuroprotective activities are molecule-specific and may contribute to the clinical efficacy of these drugs for the treatment of chronic and progressive neurodegenerative diseases in which oxidative injury and/or protein misfolding and aggregation exert a primary role.
Export Options
About this article
Cite this article as:
Ferrari-Toninelli Giulia, Bonini A. Sara, Cenini Giovanna, Maccarinelli Giuseppina, Grilli Mariagrazia, Uberti Daniela and Memo Maurizio, Dopamine Receptor Agonists for Protection and Repair in Parkinsons Disease, Current Topics in Medicinal Chemistry 2008; 8 (12) . https://dx.doi.org/10.2174/156802608785161402
DOI https://dx.doi.org/10.2174/156802608785161402 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Lipid Rafts/Caveolae in the Anticancer Effect of Endocannabinoids
Mini-Reviews in Medicinal Chemistry Monoamine Oxidases: The Biochemistry of the Proteins As Targets in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry A PPAR-β/δ Agonist is Neuroprotective and Decreases Cognitive Impairment in a Rodent Model of Parkinson’s Disease
Current Neurovascular Research <i>Nigella Sativa</i> (Black Seeds), A Potential Herb for the Pharmacotherapeutic Management of Hypertension - A Review
Current Cardiology Reviews Anesthetic Agents and Neuronal Autophagy. What We Know and What We Don't.
Current Medicinal Chemistry The Influence of Hypothalamic Cytokine PRP on Protein Synthesis in Brain Subcellular Compartments in Crush Syndrome
Central Nervous System Agents in Medicinal Chemistry Human Platelets Express Authentic CB1 and CB2 Receptors
Current Neurovascular Research Lithium Restores Age-related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome
CNS & Neurological Disorders - Drug Targets The Dualistic Nature of Immune Modulation In Alzheimers Disease: Lessons from the Transgenic Models
Current Pharmaceutical Design Meet Our Editorial Board Member:
Current Aging Science Preface
Central Nervous System Agents in Medicinal Chemistry NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Social Behavior as an Endophenotype for Psychiatric Disorders Development of Mouse Models
Current Genomics Endothelial Progenitor Cells as Potential Drug Targets
Current Drug Targets - Cardiovascular & Hematological Disorders “My Drink is Larger than Yours”? A Literature Review of Self-Defined Drink Sizes and Standard Drinks
Current Drug Abuse Reviews Tetrahydrobiopterin Biosynthesis, Utilization and Pharmacological Effects
Current Drug Metabolism Identification of Potential Dual Negative Allosteric Modulators of Group I mGluR Family: A Shape Based Screening, ADME Prediction, Induced Fit Docking and Molecular Dynamics Approach Against Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Recent Developments of Melatonin Related Antioxidant Compounds
Combinatorial Chemistry & High Throughput Screening Neurorestorative Role of Stem Cells in Alzheimer’s Disease: Astrocyte Involvement
Current Alzheimer Research